UNSPSC 51271630: Lidocaine hydrochloride anhydrous

This classification denotes a cation channel blocker and anesthetic agent with the molecular formula C14H22N2O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EC2CNF7XFP, chemically known as acetamide, 2-(diethylamino)-n-(2,6-dimethylphenyl)-, monohydrochloride, but more generally known as lidocaine hydrochloride anhydrous, which bears US NIH Compound Identifier 6314.

European Medicines Agency schedules lidocaine hydrochloride anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08507MIG. Most nations, for tariff purposes, schedule lidocaine hydrochloride anhydrous under HS 29242910. Lidocaine hydrochloride anhydrous bears US NLM identifiers UMLS ID C2756728 and NCI Concept Code C90650. SMILES: CCN(CC)CC(=O)NC1C(CCCC1C)C.CL.

UNSPSC 51271630 Lidocaine hydrochloride anhydrous is a Commodity code covering the supply of this specific pharmaceutical ingredient to state and local health systems, correctional facilities, and other government agencies. State and local governments procure lidocaine hydrochloride anhydrous primarily through cooperative purchasing vehicles that aggregate demand across multiple jurisdictions to secure volume pricing and standardized supply contracts. The work solicited under this code involves manufacturers or authorized distributors supplying the drug with specified National Drug Codes, packaging configurations, and compliance certifications, including cGMP and Drug Supply Chain Security Act adherence, with pricing submitted through fixed, net-price, or WAC-minus formats.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal on January 20, 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products, including lidocaine hydrochloride anhydrous, distributed across participating state and local government facilities in Minnesota, Oregon, and other member states. The RFP requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and mandates contractual relationships with at least two of the three, with chargeback systems in place. Proposals were due March 26, 2026, with evaluation weighted 75 percent on price competitiveness, 10 percent on fixed pricing for contract term, 5 percent on administrative fee format compliance, 5 percent on EDI capability, and 5 percent on agreement to a 3 percent administrative fee. The resulting contracts are effective July 1, 2026, for a two-year initial term with optional MMCAP extensions, and vendors must maintain insurance including $5 million commercial general liability and $2 million network security and privacy liability.